monomethyl fumarate
Selected indexed studies
- Dimethyl Fumarate vs. Monomethyl Fumarate: Unresolved Pharmacologic Issues. (Pharmaceutics, 2025) [PMID:41471022]
- Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS). (Neurol Int, 2021) [PMID:34069538]
- Dimethyl Fumarate. (, 2006) [PMID:29999794]
_Worker-drafted node — pending editorial review._
Connections
monomethyl fumarate is a side effect of
Sources
- Diroximel Fumarate. (2006) pubmed
- Dimethyl Fumarate. (2006) pubmed
- Dimethyl Fumarate. (2012) pubmed
- Dimethyl Fumarate vs. Monomethyl Fumarate: Unresolved Pharmacologic Issues. (2025) pubmed
- Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS). (2021) pubmed
- The Evolving Role of Monomethyl Fumarate Treatment as Pharmacotherapy for Relapsing-Remitting Multiple Sclerosis. (2024) pubmed
- Monomethyl fumarate confers cardioprotection after myocardial infarction via HCAR2-dependent activation of PI3K/Akt signaling. (2025) pubmed
- Site-specific drug release of monomethyl fumarate to treat oxidative stress disorders. (2025) pubmed
- Dimethyl fumarate inhibits necroptosis and alleviates systemic inflammatory response syndrome by blocking the RIPK1-RIPK3-MLKL axis. (2023) pubmed
- Monomethyl fumarate attenuates lung Ischemia/Reperfusion injury by disrupting the GAPDH/Siah1 signaling cascade. (2024) pubmed